Traws Pharma develops investigational antiviral medicines for respiratory viral diseases such as influenza and COVID-19. TRAW reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 18 | HC Wainwright & Co. | Reiterated | Hold | |
| Jun 18 | HC Wainwright & Co. | Downgrade | Hold | |
| May 20 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How TRAW has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
Whale Options Flow
90DNo whale options trades in TRAW in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TRAW is in one of them and how their past TRAW trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TRAW in an article yet. Here's the latest on the wider market.
About Traws Pharma
Traws Pharma is a clinical stage biopharmaceutical company based in Newtown, Pennsylvania. It is developing investigational antiviral medicines for respiratory viral diseases, including influenza, bird flu and COVID-19. Its main candidate, tivoxavir marboxil, is being studied as a single dose oral treatment and as a monthly oral option to prevent influenza. The company also has cancer programs in clinical development. Its candidates are aimed at patients, and none is yet approved for sale.
- Headquarters
- Newtown, PA